Cardiovascular Drugs Practice Questions

Q: Which of the following is true about quinidine?

All of the above. **Explanation:** Quinidine is a **Class IA antiarrhythmic** agent derived from the cinchona bark. It acts primarily by blocking open sodium channels (decreasing the rate of depolarization) and blocking potassium channels. * **Option A (Increases Effective Refractory Period):** By blocking potassium channels during phase 3 of the action potential, quinidine prolongs the action potential duration (APD). This directly leads to an increase in the **Effective Refractory Period (ERP)**, which is a hallmark of Class IA agents. * **Option B (Paradoxical Tachycardia):** Although quinidine is used to treat arrhythmias, it possesses significant **antimuscarinic (atropine-like) properties**. In patients with atrial flutter or fibrillation, it can enhance AV conduction and increase the ventricular rate, leading to "paradoxical tachycardia." To prevent this, it is usually co-administered with a drug that slows AV conduction (like Digoxin or Beta-blockers). * **Option C (Cinchonism):** This is a classic dose-dependent adverse effect of quinidine. Symptoms include tinnitus, hearing loss, visual disturbances, headache, and dizziness. **High-Yield Clinical Pearls for NEET-PG:** * **ECG Changes:** Quinidine causes prolongation of the **QRS complex and QT interval**. * **Torsades de Pointes:** Due to QT prolongation, it can trigger this life-threatening polymorphic ventricular tachycardia. * **Drug Interactions:** Quinidine reduces the renal clearance of **Digoxin**, leading to digoxin toxicity. * **Alpha-blocking effect:** It can cause peripheral vasodilation and hypotension. * **Hematology:** It is associated with immune-mediated thrombocytopenia.

Q: All of the following statements about beta blockers are true EXCEPT?

Atenolol is safe in renal failure.. ### Explanation **1. Why Option D is the Correct Answer (The False Statement):** Atenolol is a **highly hydrophilic (water-soluble)** beta-blocker. Unlike lipophilic drugs (like Propranolol) which are metabolized by the liver, Atenolol is primarily excreted **unchanged by the kidneys**. Therefore, in patients with renal failure, the drug accumulates, leading to toxicity (profound bradycardia and hypotension). It requires significant dose adjustment or avoidance in renal impairment. **2. Analysis of Other Options:** * **Option A (True):** Nebivolol is a third-generation, **highly cardioselective** $\beta_1$ blocker. It also possesses unique vasodilatory properties mediated by the release of Nitric Oxide (NO) from the endothelium. * **Option B (True):** Cardioselective beta-blockers (e.g., Metoprolol, Atenolol, Bisoprolol) preferentially block $\beta_1$ receptors. While they are "relatively" safe in mild-to-moderate asthma because they avoid $\beta_2$ blockade (which causes bronchospasm), they should still be used with extreme caution as selectivity is lost at higher doses. * **Option C (True):** In **acute** decompensated heart failure, beta-blockers are contraindicated because their negative inotropic effect can further worsen cardiac output. However, they are a cornerstone of therapy in **chronic** stable heart failure (specifically Metoprolol succinate, Bisoprolol, and Carvedilol). **3. NEET-PG High-Yield Pearls:** * **Lipophilic Beta Blockers:** Propranolol, Metoprolol. (Undergo extensive first-pass metabolism; cross the Blood-Brain Barrier). * **Hydrophilic Beta Blockers:** Atenolol, Sotalol, Nadolol. (Excreted by kidneys; longer half-lives). * **Shortest Acting:** Esmolol (metabolized by RBC esterases; $t_{1/2} \approx 9$ mins). * **Longest Acting:** Nadolol. * **Beta Blockers with ISA (Intrinsic Sympathomimetic Activity):** Pindolol, Acebutolol (preferred in patients with resting bradycardia).

Q: What is the primary rationale for not using an ACE inhibitor concurrently with spironolactone?

Hyperkalemia. **Explanation:** The primary rationale for avoiding the concurrent use of ACE inhibitors (ACEIs) and spironolactone is the significantly increased risk of **life-threatening hyperkalemia**. **Mechanism:** 1. **ACE Inhibitors:** These drugs block the conversion of Angiotensin I to Angiotensin II. Since Angiotensin II is the primary stimulus for **aldosterone** release from the adrenal cortex, ACEIs lead to a decrease in aldosterone levels. 2. **Spironolactone:** This is a potassium-sparing diuretic that acts as a direct **aldosterone antagonist** at the mineralocorticoid receptors in the distal tubule. 3. **Synergy:** Both drugs ultimately inhibit the action of aldosterone, which is responsible for sodium reabsorption and potassium excretion. When used together, potassium excretion is severely impaired, leading to its accumulation in the blood. **Analysis of Incorrect Options:** * **B. Hypokalemia:** This is the opposite effect. Both drugs are "potassium-sparing." * **C. Increased incidence of cough:** While ACEIs cause a dry cough (due to bradykinin accumulation), spironolactone does not contribute to this mechanism. * **D. Hypomagnesemia:** Spironolactone tends to be magnesium-sparing; it does not typically cause low magnesium. **Clinical Pearls for NEET-PG:** * **RALES Trial:** This landmark study showed that low-dose spironolactone can be used with ACEIs in severe heart failure (NYHA Class III/IV), but only under **strict monitoring** of serum potassium and creatinine. * **Contraindication:** This combination is generally avoided if serum potassium is **>5.0 mEq/L** or if there is significant renal impairment (Creatinine >2.5 mg/dL). * **Other Drugs:** ARBs (Angiotensin Receptor Blockers) and Aliskiren (Direct Renin Inhibitor) also carry the same hyperkalemia risk when combined with spironolactone.

Q: Which of the following calcium channel blocking agents is used in the treatment of hypertension?

Nifedipine. **Explanation:** **Nifedipine** is the correct answer because it belongs to the **Dihydropyridine (DHP)** class of Calcium Channel Blockers (CCBs). These drugs primarily act by blocking L-type calcium channels in the vascular smooth muscle, leading to peripheral vasodilation and a reduction in systemic vascular resistance, which effectively lowers blood pressure. **Analysis of Options:** * **Prazosin (Option A):** This is a selective **alpha-1 adrenergic blocker**. While it is used for hypertension, it is not a calcium channel blocker. It is often a drug of choice for patients with comorbid Benign Prostatic Hyperplasia (BPH). * **Lidoflazine (Option B):** This is an older, non-selective calcium channel blocker primarily used as a coronary vasodilator for angina. It is not a standard treatment for hypertension and has been largely superseded by safer agents. * **Captopril (Option C):** This is an **ACE Inhibitor**. It lowers blood pressure by preventing the conversion of Angiotensin I to Angiotensin II, not by blocking calcium channels. **High-Yield NEET-PG Pearls:** * **DHP CCBs** (Nifedipine, Amlodipine) are preferred for hypertension due to their potent vasodilator effects. * **Non-DHP CCBs** (Verapamil, Diltiazem) have more prominent effects on the heart (negative inotropy/chronotropy) and are used for arrhythmias and angina. * **Side Effects:** A common side effect of Nifedipine/Amlodipine is **ankle edema** (due to precapillary vasodilation) and reflex tachycardia. * **Clinical Note:** Short-acting Nifedipine is avoided in hypertensive emergencies due to the risk of precipitous hypotension and myocardial infarction; long-acting formulations are preferred.

Q: Calcium channel blockers act on which type of muscle?

Smooth muscle. **Explanation:** Calcium channel blockers (CCBs) primarily target **L-type voltage-gated calcium channels**. The physiological effect of these drugs is highly tissue-specific due to the different ways muscle types handle calcium for contraction. **Why Smooth Muscle is the Correct Answer:** Vascular smooth muscle relies heavily on the influx of **extracellular calcium** through L-type channels to initiate contraction. When CCBs block these channels, they prevent the calcium-calmodulin complex formation, leading to vasodilation. This makes them effective for treating hypertension and angina. CCBs also act on the **cardiac muscle** (myocardium and nodal tissue), but among the options provided, smooth muscle is the primary site of action for the dihydropyridine class (e.g., Amlodipine). **Why Other Options are Incorrect:** * **Skeletal Muscle:** Unlike smooth or cardiac muscle, skeletal muscle contraction is triggered by **intracellular calcium** released from the sarcoplasmic reticulum (via the RyR1 receptor) through a process called mechanical coupling. It does not depend on extracellular calcium influx through L-type channels; therefore, CCBs have no clinical effect on skeletal muscle strength or function. * **Both/Neither:** Since skeletal muscle is unaffected, these options are physiologically incorrect. **NEET-PG High-Yield Pearls:** * **Dihydropyridines (e.g., Nifedipine):** Act mainly on vascular smooth muscle (potent vasodilators). * **Non-Dihydropyridines (e.g., Verapamil, Diltiazem):** Act on both smooth muscle and cardiac muscle (negative inotropes and chronotropes). * **Drug of Choice:** CCBs are the preferred antihypertensives in elderly patients and those of African descent. * **Side Effect:** Peripheral edema is a common side effect of dihydropyridines due to selective precapillary vasodilation.

Q: Verapamil is associated with which of the following adverse effects?

Hyperglycemia. **Explanation:** The correct answer is **D. Hyperglycemia**. **Mechanism of Action:** Verapamil is a non-dihydropyridine Calcium Channel Blocker (CCB). While its primary action is on the L-type calcium channels in the myocardium and vascular smooth muscle, it also affects the **beta cells of the pancreas**. Insulin release from these cells is a calcium-dependent process. By blocking calcium entry into pancreatic beta cells, Verapamil inhibits the exocytosis of insulin, leading to reduced insulin secretion and subsequent **hyperglycemia**. **Analysis of Incorrect Options:** * **A. Constipation:** This is the **most common** side effect of Verapamil. It occurs due to the blockade of calcium channels in the gastrointestinal smooth muscle, leading to decreased motility. (Note: While common, the question specifically targets the metabolic side effect in this context). * **B. Headache:** This is a common side effect of dihydropyridines (like Amlodipine) due to potent peripheral vasodilation, but it is less characteristic of Verapamil. * **C. Bradycardia:** Verapamil has significant negative chronotropic and inotropic effects. While it *does* cause bradycardia, in the context of this specific MCQ, hyperglycemia is the metabolic adverse effect being tested. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Verapamil is the drug of choice for **Prophylaxis of Paroxysmal Supraventricular Tachycardia (PSVT)** and Cluster Headaches. * **Contraindication:** Never co-administer Verapamil with **Beta-blockers** as it can lead to additive depression of the SA/AV node, resulting in severe bradycardia or heart block. * **Gingival Hyperplasia:** Like Phenytoin and Cyclosporine, CCBs (especially Nifedipine and Verapamil) can cause gum enlargement.

Q: Which of the following is a limiting adverse effect of ACE inhibitors?

Hyperkalemia. ### Explanation **Correct Answer: D. Hyperkalemia** **Mechanism of Action:** ACE inhibitors (e.g., Enalapril, Lisinopril) block the conversion of Angiotensin I to Angiotensin II. A decrease in Angiotensin II leads to a subsequent reduction in **Aldosterone** secretion from the adrenal cortex. Since aldosterone is responsible for sodium reabsorption and potassium excretion in the distal nephron, its inhibition results in **potassium retention**. This can lead to clinically significant hyperkalemia, especially in patients with chronic kidney disease (CKD) or those taking potassium-sparing diuretics. **Analysis of Incorrect Options:** * **A. Acidosis:** While severe hyperkalemia can sometimes be associated with metabolic acidosis (Type 4 RTA), it is not a direct or primary limiting adverse effect of ACE inhibitors. * **B. Hypernatremia:** ACE inhibitors actually promote **natriuresis** (sodium excretion) by reducing aldosterone levels. Therefore, they are more likely to cause hyponatremia than hypernatremia. * **C. Hypokalemia:** This is the opposite of the expected effect. Hypokalemia is typically seen with diuretics like thiazides or loop diuretics, not ACE inhibitors. **High-Yield Clinical Pearls for NEET-PG:** * **The "Cough" Factor:** The most common side effect of ACE inhibitors is a **dry, hacking cough** (due to increased levels of Bradykinin and Substance P). * **Teratogenicity:** ACE inhibitors are strictly **contraindicated in pregnancy** as they cause fetal renal dysgenesis (Category X). * **Bilateral Renal Artery Stenosis:** ACE inhibitors can precipitate acute renal failure in these patients because they dilate the efferent arteriole, crashing the GFR. * **First-Dose Phenomenon:** Sudden hypotension can occur after the first dose, particularly in patients on diuretics.

Question 1

Which of the following PDE-5 inhibitors has no significant interaction with high-fat meal intake?

Accepted Answer

Tadalafil

Answer

Sildenafil

Answer

Vardenafil

Answer

All of the above

Question 2

Which of the following is true about quinidine?

Accepted Answer

All of the above

Answer

It increases effective refractory period

Answer

Causes paradoxical tachycardia

Answer

Cinchonism is seen

Question 3

All of the following statements about beta blockers are true EXCEPT?

Accepted Answer

Atenolol is safe in renal failure.

Answer

Nebivolol is a cardioselective beta blocker.

Answer

Cardioselective beta blockers are relatively safe in asthma.

Answer

Beta blockers are contraindicated in acute congestive heart failure.

Question 4

Which drug causes a decrease in the late sodium current?

Accepted Answer

Ranolazine

Answer

Nicorandil

Answer

Trimetazidine

Answer

Molsidomine

Question 5

What is the primary rationale for not using an ACE inhibitor concurrently with spironolactone?

Accepted Answer

Hyperkalemia

Answer

Hypokalemia

Answer

Increased incidence of cough

Answer

Hypomagnesemia

Question 6

Which of the following calcium channel blocking agents is used in the treatment of hypertension?

Accepted Answer

Nifedipine

Answer

Prazosin

Answer

Lidoflazine

Answer

Captopril

Question 7

Which among the following is a venodilator?

Accepted Answer

Nitroprusside

Answer

Hydralazine

Answer

Minoxidil

Answer

Lisinopril

Question 8

Calcium channel blockers act on which type of muscle?

Accepted Answer

Smooth muscle

Answer

Skeletal muscle

Answer

Both skeletal and smooth muscle

Answer

Neither skeletal nor smooth muscle

Question 9

Verapamil is associated with which of the following adverse effects?

Accepted Answer

Hyperglycemia

Answer

Constipation

Answer

Headache

Answer

Bradycardia

Question 10

Which of the following is a limiting adverse effect of ACE inhibitors?

Accepted Answer

Hyperkalemia

Answer

Acidosis

Answer

Hypernatremia

Answer

Hypokalemia

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?